¼¼°èÀÇ ¹Ý·Áµ¿¹° Áø´Ü ½ÃÀå º¸°í¼­(2025³â)
Companion Diagnostics Global Market Report 2025
»óǰÄÚµå : 1648620
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,371,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,209,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,048,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¹Ý·Áµ¿¹° Áø´Ü ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ºñ¾àÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â CAGR 21.5%, ½ÃÀå ±Ô¸ð´Â 190¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£ÀÇ ¼ºÀåÀº Ç¥Àû¿ä¹ý °³¹ß, °¨¿°Áõ Áø´Ü, Èñ±ÍÁúȯ Áø´Ü Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿¿¡ ±âÃÊÇÑ ÀǾàǰ °³¹ß Áõ°¡, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç, ¸®Äûµå ¹ÙÀ̿ɽà ÀÀ¿ë¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£ÀÇ ÁÖ¿ä µ¿Çâ¿¡´Â ¸é¿ª¿ä¹ý°ú ¸é¿ªÇÐÀÇ Áøº¸, Áø´ÜÇп¡¼­ÀÇ AI¿Í ¸Ó½Å·¯´×, Á¦Ç° À̳뺣À̼Ç, Industry 4.0ÀÇ Ã¤¿ë, Àü·«Àû Á¦ÈÞ µîÀÌ Æ÷ÇԵ˴ϴÙ.

Ç¥Àû ¿ä¹ý Áõ°¡´Â ¹Ý·Áµ¿¹° Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ç¥Àû¿ä¹ýÀ̶õ ¾Ï¼¼Æ÷ÀÇ Æ¯Á¤ Ư¡¿¡ ÃÊÁ¡À» ¸ÂÃß°í Áúº´ÀÇ ¼ºÀå°ú È®´ë¸¦ ´ÊÃß´Â ¾à¸®ÇÐÀû Á¢±ÙÀ» ¸»ÇÕ´Ï´Ù. ÀÌ ¾àÀº Àü½ÅÀ» ¼øÈ¯ÇÏÁö¸¸ È­ÇÐ ¿ä¹ýº¸´Ù Á¤È®ÇÑ È¿°ú°¡ ÀÖÀ¸¸ç ºÎÀÛ¿ëÀÌ Àû½À´Ï´Ù. »ý¹°ÇÐÀû ¸¶Ä¿¸¦ ±â¹ÝÀ¸·Î ÇÑ ¹Ý·Áµ¿¹° Áø´Ü °Ë»ç´Â °³º°È­ ¾Ï Ä¡·áÀÇ Áß¿äÇÑ ¿ä¼Ò°¡µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù ¹Ì±¹¿¡ º»»ç¸¦ µÐ º´¿ø¡¤°Ç°­ °ü¸® Á¶Á÷ÀÎ ¸ÂÃãÇü ÀÇ·á ¿¬ÇÕ(Personalised Medicine Coalition)Àº FDA°¡ Èñ±ÍÁúȯ ȯÀÚ¿¡ ´ëÇÑ »õ·Î¿î °³ÀÎÈ­ Ä¡·á¸¦ 2022³â 6°Ç¿¡ ´ëÇØ 2023³â¿¡´Â 16°Ç ½ÂÀÎÇß´Ù°í º¸°íÇß½À´Ï´Ù. ±× °á°ú, Ç¥Àû ¿ä¹ý Áõ°¡°¡ ¹Ý·Áµ¿¹° Áø´Ü ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¹Ý·Áµ¿¹° Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ´õ¿í ÃËÁøµË´Ï´Ù. ¹Ý·Áµ¿¹° Áø´ÜÀº ¸¸¼º Áúȯ°ú ºñ°¨¿°¼º Áúȯ(NCDs)¿¡¼­ Ä¡·á °èȹÀÇ Á¶Á¤, Áúº´ ÁøÇàÀÇ ¸ð´ÏÅ͸µ, ¾à¹° ³»¼ºÀÇ ¿¹Ãø¿¡ »ç¿ëµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é ¼¼°è »ç¸ÁÀÚ ¼öÀÇ 74%(4,100¸¸ ¸í)¿¡ ÇØ´çÇÏ´Â ¿¬°£ 4,100¸¸ ¸íÀÌ NCD¿¡ ÀÇÇØ À¯¹ßµÇ¾ú½À´Ï´Ù. ƯÈ÷ ½ÉÇ÷°üÁúȯ, ¾Ï, ¸¸¼ºÈ£Èí±âÁúȯ, ´ç´¢º´ µîÀÇ Áúº´ÀÌ ÀÌ ºÎ´ã¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ ÀÌȯÀ² Áõ°¡´Â ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ½ÃÀå ÀüüÀÇ ¼ºÀå¿¡ ±â¿©Çϱâ À§ÇØ µ¿¹ÝÀÚ Áø´ÜÀÌ ÇʼöÀûÀÎ ¿ªÇÒÀ» ´ã´çÇÑ´Ù´Â °ÍÀ» °­Á¶ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã °æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Companion diagnostics refer to in vitro diagnostic medical tests employed to assess the safety and effectiveness of a corresponding drug or biological product. These tests play a crucial role in helping healthcare professionals match patients with specific drugs or therapies.

The primary products and services in the companion diagnostics market include assays, kits, reagents, software, and related services. Assays, kits, and reagents find applications in various life science, environmental, and research laboratories. Assays are procedures used to examine substances for composition or quality, kits are collections of equipment and materials for specific purposes, and reagents are chemicals used in laboratory testing. Technologies such as polymerase chain reaction, next-generation sequencing, in situ hybridization, and immunohistochemistry are employed in companion diagnostics. These diagnostic tools are instrumental in identifying various cancer diseases like lung, breast, colorectal, leukemia, and melanoma. The primary users of companion diagnostics include pharmaceutical and biopharmaceutical companies, reference laboratories, and contract research organizations.

The companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides companion diagnostics market statistics, including companion diagnostics industry global market size, regional shares, competitors with a companion diagnostics market share, detailed companion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the companion diagnostics industry. This companion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion diagnostics market size has grown rapidly in recent years. It will grow from $7.34 billion in 2024 to $8.75 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to increased adoption of personalized medicine, growth of oncology and cancer therapies, increased pharmaceutical r&d collaboration, precision medicine initiatives, and biomarker discovery.

The companion diagnostics market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 21.5%. The growth in the forecast period can be attributed to targetedTherapy development, infectious disease diagnostics, increasing rare disease diagnostics, increasing biomarker-based drug development, point-of-care testing, and liquid biopsy applications. Major trends in the forecast period include immunotherapy and immunology advances, ai and machine learning in diagnostics, product innovations, adoption of industry 4.0, strategic collaborations.

The rising number of targeted therapies is anticipated to drive the growth of the companion diagnostics market. Targeted therapy refers to a pharmacological approach that focuses on specific characteristics of cancer cells to slow down the disease's growth and spread. While these medications circulate throughout the body, they have a more precise effect than chemotherapy and often result in fewer side effects. Companion diagnostic testing based on biological markers is becoming a crucial component of personalized cancer care. For example, in February 2024, the Personalised Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six in 2022. Consequently, the increase in targeted therapies is fueling growth in the companion diagnostics market.

The growth of the companion diagnostics market is further propelled by the rising prevalence of chronic diseases. Companion diagnostics are increasingly used in chronic diseases or non-communicable diseases (NCDs) to tailor treatment plans, monitor disease progression, and predict drug resistance. The World Health Organization reported that 74% of global deaths, equivalent to 41 million, are caused by NCDs annually. Notably, diseases such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this burden. The rising incidence of chronic diseases underscores the essential role of companion diagnostics in enhancing patient outcomes and contributing to the overall growth of the market.

A key trend in the companion diagnostics market is technological advancement, particularly the integration of artificial intelligence (AI). AI is being leveraged to develop more efficient drugs and advance companion diagnostics. The extensive genetic profiling data sets, continuously generated, enable the application of AI to identify insights into disease causes. For example, Toronto-based start-up Deep Genomics is utilizing AI to expedite the discovery of better medications for genetic illnesses. Through deep learning, scientists can explore the human genome, analyze billions of chemical compounds, and identify promising formulations for clinical trials. This application of AI in companion diagnostics aligns with the broader trend of technological innovation, driving advancements in the field.

Major players in the companion diagnostics market are joining forces to create innovative treatment solutions aimed at enhancing personalized medicine, improving patient outcomes, and optimizing the effectiveness of targeted therapies. This collaboration among companies will accelerate the development and commercialization of companion diagnostics (CDx) for hematology and oncology treatments. For instance, in January 2024, Agilent Technologies, Inc., a California-based company providing instruments, software, services, and consumables for laboratories, announced a partnership with Incyte, a US-based pharmaceutical company. This collaboration combines Agilent's expertise and established track record in developing companion diagnostics (CDx) to support Incyte's hematology and oncology portfolio. As a result, Agilent will expand its CDx portfolio with new biomarkers, while Incyte will leverage Agilent's proficiency in assay development, regulatory approvals, and commercialization to facilitate clinical trials and CDx registration in the U.S. and Europe.

In August 2022, Genome Diagnostics, a UK-based testing company that offers personalized health insights to assist with diagnosis, treatment, and drug discovery, acquired Eurobio Scientific for USD 148.22 million. This acquisition allows GenDx to broaden its global presence, strengthen customer support in transplant diagnostics, and sustain its R&D and educational initiatives. Eurobio Scientific is a France-based company specializing in the research, development, and marketing of diagnostic products and life-science research products.

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The companion diagnostics market includes revenues earned by theranostics and monitoring tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Companion Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for companion diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The companion diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Companion Diagnostics Market Characteristics

3. Companion Diagnostics Market Trends And Strategies

4. Companion Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Companion Diagnostics Growth Analysis And Strategic Analysis Framework

6. Companion Diagnostics Market Segmentation

7. Companion Diagnostics Market Regional And Country Analysis

8. Asia-Pacific Companion Diagnostics Market

9. China Companion Diagnostics Market

10. India Companion Diagnostics Market

11. Japan Companion Diagnostics Market

12. Australia Companion Diagnostics Market

13. Indonesia Companion Diagnostics Market

14. South Korea Companion Diagnostics Market

15. Western Europe Companion Diagnostics Market

16. UK Companion Diagnostics Market

17. Germany Companion Diagnostics Market

18. France Companion Diagnostics Market

19. Italy Companion Diagnostics Market

20. Spain Companion Diagnostics Market

21. Eastern Europe Companion Diagnostics Market

22. Russia Companion Diagnostics Market

23. North America Companion Diagnostics Market

24. USA Companion Diagnostics Market

25. Canada Companion Diagnostics Market

26. South America Companion Diagnostics Market

27. Brazil Companion Diagnostics Market

28. Middle East Companion Diagnostics Market

29. Africa Companion Diagnostics Market

30. Companion Diagnostics Market Competitive Landscape And Company Profiles

31. Companion Diagnostics Market Other Major And Innovative Companies

32. Global Companion Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Companion Diagnostics Market

34. Recent Developments In The Companion Diagnostics Market

35. Companion Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â